{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:37:50Z","timestamp":1777891070319,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Pediatr"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated for the treatment of juvenile idiopathic arthritis (JIA). However, the effect of NSAIDs on blood pressure (BP) in children has not been rigorously examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, double-blind, multicenter, active-controlled, 6-week trial, the safety and efficacy of celecoxib (50 mg twice daily [bid] or 100 mg bid) or naproxen (7.5 mg\/kg bid) was evaluated in patients aged 2\u201317 years with JIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The least squares (LS) mean difference (celecoxib \u2013 naproxen) in change from baseline to week 6\/final visit in systolic BP was 1.10 (90% confidence interval, -0.56, 2.76). No significant LS mean differences in diastolic BP relative to baseline were reported. Treatment-emergent adverse events occurred in 48% of patients in each treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both celecoxib and naproxen had no impact on BP, and both treatments had comparable safety profiles. Celecoxib, or naproxen, could be seen as suitable treatment options for pediatric patients with JIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4137\/cmped.s20720","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T16:13:28Z","timestamp":1430756008000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Celecoxib or Naproxen on Blood Pressure in Pediatric Patients with Juvenile Idiopathic Arthritis"],"prefix":"10.4137","volume":"9","author":[{"given":"B.","family":"Falkner","sequence":"first","affiliation":[{"name":"Department of Medicine and Pediatrics, Thomas Jefferson University, Philadelphia, PA USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Berger","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Bhadra","family":"Brown","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Iorga","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.W.","family":"Nickeson","sequence":"additional","affiliation":[{"name":"AII Children's Hospital, St Petersburg, FL, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zemel","sequence":"additional","affiliation":[{"name":"Connecticut Children's Medical Center, Hartford, CT, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,5,4]]},"reference":[{"key":"bibr1-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32832f4f6b"},{"key":"bibr2-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2136"},{"key":"bibr3-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-009-1200-3"},{"key":"bibr4-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"bibr5-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.01.052"},{"key":"bibr6-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.3.475"},{"key":"bibr7-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.8.874"},{"key":"bibr8-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3283373016"},{"key":"bibr9-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000032940.33466.12"},{"key":"bibr10-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-12-93"},{"key":"bibr11-CMPed.S20720","unstructured":"US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). 2005. US FDA website. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm103420.htm. Accessed February 8, 2013."},{"key":"bibr12-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1186\/ar1704"},{"key":"bibr13-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080073"},{"issue":"2","key":"bibr14-CMPed.S20720","first-page":"390","volume":"31","author":"Petty R.E.","year":"2004","journal-title":"J Rheumatol."},{"key":"bibr15-CMPed.S20720","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"}],"container-title":["Clinical Medicine Insights: Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMPed.S20720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/CMPed.S20720","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMPed.S20720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:53:21Z","timestamp":1777614801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4137\/CMPed.S20720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":15,"alternative-id":["10.4137\/CMPed.S20720"],"URL":"https:\/\/doi.org\/10.4137\/cmped.s20720","relation":{},"ISSN":["1179-5565","1179-5565"],"issn-type":[{"value":"1179-5565","type":"print"},{"value":"1179-5565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"article-number":"CMPed.S20720"}}